^
Association details:
Evidence:
Evidence Level:
Sensitive: C4 – Case Studies
New
Title:

Two clinically distinct cases of infant hemispheric glioma carrying ZCCHC8:ROS1 fusion and responding to entrectinib

Published date:
02/23/2022
Excerpt:
In our first patient, a 1-month-old female, the tumor was diagnosed as an intracranial mass on routine neurosonography….Histopathological examination was consistent with HGG with epithelioid and rhabdoid features. The RNA sequencing revealed a ZCCHC8:ROS1 fusion...Entrectinib (supplied by Roche via a compassionate use program) was administered in 300 mg daily doses. To date, the patient remains clinically stable on entrectinib for 11 months, with no signs of recurrence on MRI and no treatment-related adverse events.
DOI:
https://doi.org/10.1093/neuonc/noac026